Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ARGX argenx SE
383.040+0.940+0.25%
Trading Session
01/27 13:12 ET
High
384.860
Open
371.850
Turnover
61.55M
Low
371.850
Pre Close
382.100
Volume
163.20K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
European Equities Move Lower Friday, Set to End Week in Negative Territory
10:59 AM EST, 01/27/2023 (MT Newswires) -- European equities were trading lower Friday, poised to end the week in negative territory, as American depositary receipts of European stocks were down 0.64%
Piper Says No Change to Positive Argenx Outlook Despite 'Puzzling' PDUFA Pushout
JMP Securities Keeps Their Buy Rating on Argenx Se (ARGX)
Sector Update: Health Care Stocks Flat to Lower Premarket Friday
09:08 AM EST, 01/27/2023 (MT Newswires) -- Health care stocks were flat to lower premarket Friday. The Health Care Select Sector SPDR Fund (XLV) was 0.1% lower and the iShares Biotechnology ETF (IBB)
Argenx Stock Dips as FDA Extends Review Period for Subcutaneous Efgartigimod
Argenx Announces FDA Extension of Efgartigimod BLA Review
Argenx Says US FDA Lenghtens Review for Investigational Treatment of Generalized Myasthenia Gravis
04:14 AM EST, 01/27/2023 (MT Newswires) -- Argenx (ARGX) said Friday that the US Food and Drug Administration has extended the review of a biologics license application for subcutaneous efgartigimod f
Argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
January 27, 2023 Amsterdam, the Netherlands — argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that
Cowen Adjusts Price Target on Argenx to $458 From $441, Maintains Outperform Rating
10:21 AM EST, 01/25/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
ArGEN-X Price Target Raised to $458.00/Share From $441.00 by Cowen & Co.
Company Overview
More
argenx SE operates as a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. It operates from the Netherlands, Belgium, the United States of America, Japan, Switzerland, Germany and France. The firm partnering with academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. It evaluates efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.
CEO： Mr. Tim Van Hauwermeiren
Market： NASDAQ
Listing Date： 05/18/2017
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet